Table 1.
Clinical trials of mRNA vaccines against infectious diseases.
| Name | Sponsoring institution | Type | Target | Phase |
|---|---|---|---|---|
| CV7201 | CureVac AG | RNActive viral Ag mRNA | Rabies virus | Phase I (NCT02241135) |
| CV7202 | CureVac AG | Liposome-complexed Ag mRNA | Rabies virus | Phase I (NCT03713086) |
| GSK3903133A | GSK | self-amplifying mRNA in cationic nanoemulsion | Rabies virus | Phase I (NCT04062669) |
| VAL-339851 | Moderna | Nucleoside-modified viral Ag mRNA | Influenza virus(H7N9) | Phase I (NCT03345043) |
| VAL-506440 | Moderna | Nucleoside-modified viral Ag mRNA | Influenza virus(H10N8) | Phase I (NCT03076385) |
| mRNA-1345 | Moderna | Nucleoside-modified viral Ag mRNA | Respiratory Syncytial Virus | Phase I (NCT04528719) Phase II & III (NCT05127434) |
| mRNA-1647 | Moderna | Nucleoside-modified viral Ag mRNA | Cytomegalovirus | Phase II (NCT04232280) Phase III (NCT05085366) |
| mRNA-1443 | Moderna | Nucleoside-modified viral Ag mRNA | Cytomegalovirus | Phase I (NCT03382405) Phase II (NCT04917861) |
| mRNA-1653 | Moderna | Nucleoside-modified viral Ag mRNA | Human Metapneumovirus and Human Parainfluenza Infection | Phase I (NCT04144348, NCT03392389) |
| mRNA-1325 | Moderna | Nucleoside-modified viral Ag mRNA | Zika virus | Phase I (NCT03014089) |
| mRNA-1893 | Moderna | Nucleoside-modified viral Ag mRNA | Zika virus | Phase I (NCT04064905) Phase II (NCT04917861) |
| mRNA-1944 | Moderna | Nucleoside-modified viral Ag mRNA | Chikungunya | Phase I (NCT03829384) |
| mRNA-1388 | Moderna | Nucleoside-modified viral Ag mRNA | Chikungunya | Phase I (NCT03325075) |